Elsevier Launches Next Generation Codifa, Providing Italian Doctors with Real Time Access to Critical Drug Information

Codifa enables Italian professionals to take better decisions in a shorter time

Milan, August 3, 2011 – Elsevier, the world-leading global provider of scientific, technical, and medical information products and services, announced today a new release of Codifa, an easy to use and powerful online point of care drug information platform serving Italian healthcare providers.

"We are delighted to provide real time access to critical data on drugs, tailored to a specific clinical setting and patient’s needs,” said Emile Blomme, Managing Director, Elsevier Italy. “Codifa will greatly improve the appropriateness of care, help reduce risk, optimize operating costs and ultimately diminish malpractice liability.”

This project is part of Elsevier’s continuous efforts to offer most qualified and relevant international contents to its local or multi-language clinical products in Europe. Codifa’s critical drug information reduces the clinical risk associated with errors in prescribing or administering drugs, adverse reactions and suboptimal dosages.

The new Codifa system improves significantly the core functionalities and contents of the 2005 release, providing a new user-friendly interface and search engine designed to enhance and speed up information retrieval, reading, integration in workflows and use on handheld devices. Longstanding partnerships with important, Italian and international, institutions and associations (both public and private) ensure that Codifa provides authoritative, information on drug interactions, global brand name conversion, generic drug search and price trends.

About Elsevier

Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence,and ClinicalKey—and publishes over 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.

The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Media contact
Ludovico Baldessin
Digital Business Solutions Director, Elsevier
+39 02 88184 354
l.baldessin@elsevier.com